Latest KFF Health News Content

Latest KFF Health News Stories

HHS Nominee Talks Tough Against Pharma’s Profit Tactics, But History At Drugmaker Tells Different Story

Morning Briefing

Alex Azar, the Trump administration’s pick to head the Department of Health and Human Services, is set to testify before the Senate Finance Committee this week, where it’s likely his close ties to the pharmaceutical industry will take center stage with his critics.

Drug Overdose Deaths Soar Nationally But Plateau In Some Western States

KFF Health News Original

Fatalities are climbing in states that have been flooded by the deadly opioid fentanyl, but are remaining flat — or even falling — in many Western states, where the drug has not yet been as common as other parts of the country.

La administración Trump busca frenar el creciente negocio de la marihuana

KFF Health News Original

El fiscal general de Estados Unidos, Jeff Sessions, anuló una norma de la era Obama con la cual se desalentó a los fiscales federales a tomar medidas enérgicas contra la venta y el consumo de marihuana.

Parsing The Policies: Trump And Association Health Plans; What About Out-Of-Pocket Health Care Costs?

Morning Briefing

Opinion writers examine a range of health policy issues, including the Trump administration’s proposed rule to pave the way for the creation of more association health plans and a push for Congress to restore funding for the Children’s Health Insurance Program.

While Cancer Deaths Are Decreasing, U.S.’s No. 2 Killer Still Remains Formidable Foe

Morning Briefing

Experts credit a decline in tobacco use for the improved rates, along with breakthrough drugs that have improved the chance of surviving a diagnosis. In other public health news: the IV bag shortage linked to the hurricane in Puerto Rico may be over soon; a study finds that antioxidants don’t ease muscles after exercise; and more.

Pipeline Of Generics Into Drug Marketplace Contributing To Lower Prices, CVS And Walgreens Say

Morning Briefing

But the influx of the medications might help the companies’ bottom lines because generics generally have a higher margin than name-brand drugs. Meanwhile, the industry is primed for another wave of mega-mergers in the coming year.